Subintimal excimer laser coronary atherectomy (S-ELCA) as a bail-out for device-uncrossable chronic total occlusion: case report
Abstract
Background: Chronic total occlusion (CTO) that cannot be crossed with balloons or microcatheters despite successful guidewire passage represent one of the most challenging scenarios in percutaneous coronary intervention (PCI). Excimer laser coronary angioplasty (ELCA) is an established adjunct for device-uncrossable lesions; however, the safety of its application within the subintimal space remains limited.
Case summary: A 67-year-old male with a complex cardiac history, including prior recurrent interventions and coronary artery bypass grafting, was referred for staged PCI of a right coronary artery CTO because of refractory angina (Canadian Cardiovascular Society class III). Following successful antegrade subintimal wire tracking and re-entry using a Stingray balloon, multiple ultra-low-profile balloons and dedicated microcatheters failed to traverse the subintimal-to-true-lumen transition. A 0.9-mm ELCA catheter at 80 mJ/mm2 and 80 Hz was used in the subintimal space without saline flush, successfully creating a traversable channel. Complete revascularization was achieved using six overlapping drug-eluting stents, optimized with intravascular ultrasound guidance. At two-year follow-up, repeat intravascular ultrasound demonstrated vascular healing at the subintimal-re-entry interface.
Discussion: This case demonstrates the potential safety and feasibility of subintimal ELCA (SELCA) as a bail-out for device-uncrossable lesions during antegrade dissection re-entry of…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.